Author ORCID Identifier
School of Medicine
Ipilimumab is a monoclonal antibody that works as an immunotherapeutic agent through selective targeting of T cells to strengthen the response to metastatic melanoma. It is well known that this pharmaceutical agent can cause the adverse effect of colitis. We report a rare presentation of ileocolitis refractory to both glucocorticosteroids and infliximab with a resultant pneumatosis and perforation requiring subtotal colectomy and end ileostomy.
Digital Commons Citation
Poushanchi, Behdod; Vallabh, Hiren; and Reynolds, Gorman Joel, "A Severe Case of Ipilimumab-Induced Ileocolitis Refractory to Glucocorticosteroids and Infliximab" (2018). Faculty & Staff Scholarship. 2094.
Poushanchi, B., Vallabh, H., & Reynolds, G. J. (2018). A Severe Case of Ipilimumab-Induced Ileocolitis Refractory to Glucocorticosteroids and Infliximab. Case Reports in Gastrointestinal Medicine, 2018, 1–3. https://doi.org/10.1155/2018/2431503